Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Brooks L. S. Rademacher"'
Autor:
Brooks L. S. Rademacher, Kristine M. Eilers, Julie N. Graff, Tomasz M. Beer, Joshi J. Alumkal, Renee C. Prins, Solange Mongoue-Tchokote
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 30:33-37
We previously reported that higher serum concentrations of C-reactive protein (CRP) are associated with shorter survival in men with castration-resistant prostate cancer (CRPC). To confirm this finding in an independent data set, we used 119 CRPC pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d02d4183df6d7388fefcec6ab62bdd4
https://doi.org/10.1016/j.urolonc.2009.11.012
https://doi.org/10.1016/j.urolonc.2009.11.012
Autor:
Ladan Fazli, Catherine A. O’Brien, Stephen Lieberman, Celestia S. Higano, Nicole Janeba, Mark Garzotto, Paul H. Lange, Brooks L. S. Rademacher, Tomasz M. Beer
Publikováno v:
Cancer. 116:1699-1708
BACKGROUND: A study was conducted to determine the 5-year recurrence-free survival in patients with high-risk prostate cancer after neoadjuvant combination chemotherapy followed by surgery. Secondary endpoints included safety, pathologic effects of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c01c247d27b949f1f141645abf3627f
https://doi.org/10.1002/cncr.24960
https://doi.org/10.1002/cncr.24960
Autor:
Catherine A. O’Brien, Brooks L. S. Rademacher, Celestia S. Higano, Lawrence D. True, Tomasz M. Beer, Mark Garzotto
Publikováno v:
American Journal of Clinical Pathology. 133:654-661
Clinical trials are evaluating the effect of neoadjuvant chemotherapy on men with high-risk prostate cancer. Little is known about the clinical significance of postchemotherapy tumor histopathologic features. We assessed the prognostic and predictive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f65c485af523e7debe83e933046d2480
https://doi.org/10.1309/ajcp8el5ftzsobih
https://doi.org/10.1309/ajcp8el5ftzsobih
Autor:
Tomasz M. Beer, Chung Ying Huang, Celestia S. Higano, Janét Pittsenbarger, Peter S. Nelson, David Z. Qian, Brooks L. S. Rademacher, Anne Myrthue, Mark Garzotto
Publikováno v:
The Prostate. 70:433-442
Background Metastatic prostate cancer is either inherently resistant to chemotherapy or rapidly acquires this phenotype after chemotherapy exposure. In this study, we identified a docetaxel-induced resistance mechanism centered on CCL2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45ec30746ae3237abeb8db8eb3dfd2d5
https://doi.org/10.1002/pros.21077
https://doi.org/10.1002/pros.21077
Publikováno v:
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 27:467-472
Previous studies in crosses between the C57BL/6J (B6) and the DBA/2J (D2) mice have implicated a role of the genes encoding for the 67- and 65-kDa isoforms of the glutamate decarboxylase (Gad1 and Gad2) in the manifestation and severity of multiple e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::935bc2b81a7a969d199b5cbb46843d4c
https://doi.org/10.1016/s0278-5846(03)00034-4
https://doi.org/10.1016/s0278-5846(03)00034-4
Publikováno v:
Psychopharmacology. 160:398-407
Rationale: Alcoholism is associated with withdrawal (physical dependence), tolerance, or a maladaptive pattern of alcohol (ethanol) use. The well-documented difference in susceptibility to withdrawal after chronic ethanol exposure between the C57BL/6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80c9dd744e694313cb7c0e1a0ed1cd19
https://doi.org/10.1007/s00213-001-0988-8
https://doi.org/10.1007/s00213-001-0988-8
Autor:
Janét Pittsenbarger, Brooks L. S. Rademacher, Marie C. Lafortune, Anne Myrthue, Chung Ying Huang, Mark Garzotto, Hao Geng, Tomasz M. Beer, Peter S. Nelson, Christopher T. Harvey, David Z. Qian
Publikováno v:
Cancer research. 70(8)
To identify potential mechanisms underlying prostate cancer chemotherapy response and resistance, we compared the gene expression profiles in high-risk human prostate cancer specimens before and after neoadjuvant chemotherapy and radical prostatectom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c5f2a7fddc44db077e3082b5fa0f977
https://pubmed.ncbi.nlm.nih.gov/20388787
https://pubmed.ncbi.nlm.nih.gov/20388787
Autor:
Janét Pittsenbarger, Anne Myrthue, Brooks L. S. Rademacher, David Z. Qian, Bozena Kutyba-Brooks, Tomasz M. Beer, Marin L. Gantner
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(11)
1,25-Dihydroxyvitamin D3 [1,25(OH)2D3], the most active metabolite of vitamin D3, has significant antitumor activity in a broad range of preclinical models of cancer. In this study, we show that the Iroquois homeobox gene 5 (Irx5) is down-regulated b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb84bc7047da847f705931be46e423fe
https://pubmed.ncbi.nlm.nih.gov/18519790
https://pubmed.ncbi.nlm.nih.gov/18519790
Autor:
David Z. Qian, Janét Pittsenbarger, Peter T. Nelson, Brooks L. S. Rademacher, Hao Geng, Celestia S. Higano, Tomasz M. Beer, Mark Garzotto
Publikováno v:
Journal of Clinical Oncology. 28:4548-4548
4548 Background: To identify mechanisms underlying prostate cancer chemotherapy response and resistance, we compared the gene expression in individual human prostate cancer specimens before and aft...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07f8f6e5a8cf735ce89b672496ec02a3
https://doi.org/10.1200/jco.2010.28.15_suppl.4548
https://doi.org/10.1200/jco.2010.28.15_suppl.4548
Autor:
Paul H. Lange, Brooks L. S. Rademacher, Stephen Lieberman, Celestia S. Higano, N. Janeba, Tomasz M. Beer, Mark Garzotto, Ladan Fazli, Catherine A. O’Brien
Publikováno v:
Journal of Clinical Oncology. 27:5121-5121
5121 Background: Efforts to incorporate systemic therapy with activity against castration-resistant prostate cancer into the early management of high-risk disease are motivated by persistent risk of relapse when neoadjuvant androgen suppression thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60eaa556c4b90913642cf97f22959c10
https://doi.org/10.1200/jco.2009.27.15_suppl.5121
https://doi.org/10.1200/jco.2009.27.15_suppl.5121